References
- Bohanec Grabar P , GrabnarI, RozmanB et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-cyano3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A177 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab. Dispos. 37 , 2061–2068 (2009).
- Kim KA , JooHJ, ParkJY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur. J. Clin. Pharmacol.67 , 129–134 (2011).
- Kalgutkar AS , NguyenHT, VazAD et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos.31 , 1240–1250 (2003).
- Iwamoto M , HommaS, AsanoY, MinotaS. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand. J. Rheumatol.34 , 410–411 (2005).
- Russo P , WieseM, SmithM et al. Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: a pharmacokinetic and pharmacogenetic study. Ann. Pharmacother. 47(3) , e15 (2013).
References
- Pyrpasopoulou A , BalaskaE, TriantafyllouA, AnyfantiP, AslanidisS, DoumaS. B-cell activating factor levels in rheumatoid arthritis patients in response to treatment with biologics. J. Interferon Cytokine Res.32 , 338–340 (2012).
- Pieper K , GrimbacherB, EibelH. B-cell biology and development. J. Allergy Clin. Immunol.131 , 959–971 (2013).
- Clark WB , Brown-GentryKD, CrawfordDC et al. Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood 118(4) , 1140–1144 (2011).
- Ruyssen-Witrand A , RouanetS, CombeB et al. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford) 52(4) , 636–641 (2013).
- Fabris M , QuartuccioL, SaraccoM et al. BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Arthritis Rheum. 60 , 1678 (2009).
References
- Quartuccio L , FabrisM, PontariniE et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202435 (2013) (Epub ahead of print).
- Leandro MJ . B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res. Ther.15(Suppl. 1) , S3 (2013).
- Koene HR , KleijerM, AlgraJ et al. Fc γRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype. Blood 90 , 1109–1114 (1997).
- Ruyssen-Witrand A , RouanetS, CombeB et al. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann. Rheum. Dis. 71 , 875–877 (2012).
- Sarsour K , GreenbergJ, JohnstonJA et al. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. Clin. Exp. Rheumatol. 31 , 189–194 (2013).
References
- Sarsour K , GreenbergJ, JohnstonJA et al. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-αantagonist therapies. Clin. Exp. Rheumatol. 31(2) , 189–194 (2013).
- Quartuccio L , FabrisM, PontariniE et al. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012–202435 (2013) (Epub ahead of print).
- Greenberg JD , HarroldLR, BentleyMJ et al. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford) 48 , 686–690 (2009).
- Cañete JD , SuárezB, HernándezMV et al. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68 , 1547–1552 (2009).
- Kastbom A , BrattJ, ErnestamS et al. Fcγ receptor type IIIA genotype and response to tumor necrosis factor α-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum. 56 , 448–452 (2007).